HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
rs56k8HRjgWf45YP